Abstract 91P
Background
To estimate the optimal adjuvant chemotherapy in patients with high-risk stage II and III colon adenocarcinoma, we use a propensity score-matched (PSM), nationwide, population-based cohort study to estimate different adjuvant treatments in high-risk stage II or stage III colon adenocarcinoma.
Methods
We minimized the confounding effects with PSM of sex, age, pathologic stages, tumor locations, total cycles of chemotherapy, and Charlson comorbidity index in various adjuvant treatments outcomes in patients with high-risk stage II and III resctable colon adenocarcinoma from the Taiwan Cancer Registry database by dividing them as follows: group 1, those undergoing surgery alone; group 2, those undergoing adjuvant fluoropyrimidine alone; group 3, those receiving adjuvant oxaliplatin, fluoropyrimidine, and leucovorin (FOLFOX) and group 4 those receiving adjuvant folinic acid, fluorouracil, irinotecan (FOFIRIL).
Results
In both univariate and multivariate Cox regression analyses, adjusted HRs (aHRs) derived for mortality and 95% confidence intervals (CIs), reported as aHR (95% CI), derived for surgery alone, adjuvant fluoropyrimidine alone, and adjuvant FOLFIRI groups compared with the adjuvant FOLFOX group were 1.55 (1.32-1.82), 1.22 (1.05-1.43), and 2.97 (2.43-3.63), respectively. After stratified subgroup analysis, at high-risk stage II, the aHR (95% CI) derived for mortality was 0.52 (0.30-0.89) for the adjuvant fluoropyrimidine alone group compared with the group 3.
Conclusions
Adjuvant fluoropyrimidine alone were more suitable for patients with high-risk stage II colon adenocarcinoma rather than other adjuvant chemotherapy regimens. Adjuvant FOLFOX could be the optimal regimen for patients with pathologic stage III colon adenocarcinoma whatever elderly, sex, or tumor locations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
Presenter: Filipa Pontes
Session: Poster display session
Resources:
Abstract
305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
Presenter: Tetsuro Wakasugi
Session: Poster display session
Resources:
Abstract
306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
Presenter: Lin Gui
Session: Poster display session
Resources:
Abstract
307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
Presenter: Mahmoud KhalafAllah
Session: Poster display session
Resources:
Abstract
308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Presenter: Yi-Fang Huang
Session: Poster display session
Resources:
Abstract
309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Presenter: Ai Horinouchi
Session: Poster display session
Resources:
Abstract
310P - Laser and PDT for the oral leukoplakia
Presenter: Sadykov Rasul
Session: Poster display session
Resources:
Abstract
311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
Presenter: Priscilla Caguioa
Session: Poster display session
Resources:
Abstract
312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
Presenter: Shanavas Palliyal
Session: Poster display session
Resources:
Abstract
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract